Cytokine receptor and JAK/STAT pathway mutations in acute myeloid leukemia: Prevalence and clinical impact [0.03%]
细胞因子受体和JAK/STAT通路在急性髓系白血病中的突变及其临床意义
Moath Albliwi,Daniel P Nurse,Emily C Zabor et al.
Moath Albliwi et al.
Background: Mutations in cytokine receptor and JAK/STAT; Cy-JAK/STAT) signaling genes drive myeloproliferative neoplasms (MPNs) but remain incompletely characterized in acute myeloid leukemia (AML). The authors evaluated ...
Testosterone and docetaxel treatment effect on mortality risk in nonmetastatic high-risk prostate cancer: A predictive biomarker analysis [0.03%]
睾丸激素和多西他赛治疗对高危非转移性前列腺癌患者生存率影响的预测生物标志物分析
Johnathan Zeng,Ming-Hui Chen,Jing Wu et al.
Johnathan Zeng et al.
Background: Prostate cancer (PC) arising in patients with low testosterone is often more aggressive and less responsive to androgen deprivation therapy (ADT). This study evaluated whether baseline testosterone group (low ...
Randomized Controlled Trial
Cancer. 2026 Jun 1;132(11):e70469. DOI:10.1002/cncr.70469 2026
Understudied and overlooked: Addressing sexual quality of life for couples facing metastatic breast cancer [0.03%]
被忽视的问题：改善转移性乳腺癌患者夫妻性生活质量的研究与对策分析
Kristin E Rojas
Kristin E Rojas
Editorial
Cancer. 2026 Jun 1;132(11):e70450. DOI:10.1002/cncr.70450 2026
Bridging the gap to improve skin cancer prevention practices in childhood cancer survivors [0.03%]
改善儿童癌症幸存者皮肤癌预防实践的缺口
Alan C Geller
Alan C Geller
Editorial
Cancer. 2026 Jun 1;132(11):e70451. DOI:10.1002/cncr.70451 2026
Cost-effectiveness of vorasidenib in treatment of isocitrate dehydrogenase-mutated low-grade glioma [0.03%]
伏拉西迪尼治疗异柠檬酸脱氢酶突变低级别胶质瘤的性价比分析研究论文
Adam C Kessel,Hayeon Kim,Paul D Brown et al.
Adam C Kessel et al.
Background: Vorasidenib is Food and Drug Administration-approved for treatment of grade 2 isocitrate dehydrogenase (IDH)-mutant gliomas and has demonstrated a benefit in progression-free survival compared to a placebo. Th...
Integration of venetoclax into a fludarabine and melphalan conditioning regimen in patients aged 50 years and older with acute myeloid leukemia and myelodysplastic syndrome: Results from a phase 2 clinical trial [0.03%]
一项针对50岁及以上急性髓系白血病和骨髓增生异常综合征患者的二期临床试验结果：将Venclyxto纳入氟达拉滨和美法仑预处理方案中的整合效应研究
Xiaoyu Lai,Panpan Zhu,Luxin Yang et al.
Xiaoyu Lai et al.
Background: The optimal regimens for older adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) before allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain uncertain. ...
Clinical Trial
Cancer. 2026 Jun 1;132(11):e70467. DOI:10.1002/cncr.70467 2026
Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3 [0.03%]
Elranatamab治疗复发/难治多发性骨髓瘤患者的疗效和安全性：MagnetisMM-3研究的美国亚组分析
Ajay K Nooka,Christopher Strouse,Sarah M Larson et al.
Ajay K Nooka et al.
Introduction: Elranatamab, approved for relapsed or refractory multiple myeloma, demonstrated deep, durable responses and manageable safety in patients without prior B-cell maturation antigen (BCMA)-directed therapy (BCMA...
Clinical Trial
Cancer. 2026 Jun 1;132(11):e70442. DOI:10.1002/cncr.70442 2026
Early results support base-edited anti-CD7 CAR T-cell therapy in T-cell ALL [0.03%]
基于碱基编辑的抗-CD7 CAR-T细胞治疗T细胞白血病的早期结果支持其有效性
Leah Lawrence
Leah Lawrence